Compare ZNB & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZNB | KALA |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.5M |
| IPO Year | 2018 | 2017 |
| Metric | ZNB | KALA |
|---|---|---|
| Price | $0.43 | $3.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 164.5K |
| Earning Date | 10-19-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.07 |
| 52 Week High | $9.78 | $191.00 |
| Indicator | ZNB | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 35.09 | 77.25 |
| Support Level | $0.22 | $2.07 |
| Resistance Level | $1.93 | $3.71 |
| Average True Range (ATR) | 0.21 | 0.14 |
| MACD | -0.01 | 0.38 |
| Stochastic Oscillator | 6.67 | 73.26 |
Zeta Network Group consist principally of cryptocurrency mining. The company conducts business as two operating segments which comprise of consulting services and cryptocurrency mining. Majority of revenue comes from cryptocurrency mining segment.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.